Peptides for PCT: HPG Axis Recovery and the Honest Evidence

How peptide Targets Peptides for Post-Cycle Therapy & HPG Axis Recovery

PCT (post-cycle therapy) is the off-label practice of restoring hypothalamic-pituitary-gonadal (HPG) axis function after a period of exogenous androgen use. Standard PCT pharmacology — SERMs (clomiphene, tamoxifen), aromatase inhibitors, hCG — is well-established. Peptides occupy a smaller, often-overstated role in this space. Here's what the evidence actually supports.

Gonadorelin (GnRH) directly stimulates LH and FSH release from the pituitary. It is FDA-approved for diagnostic use in HPG axis function and is sometimes used in fertility induction. As a PCT tool, it can produce pulsatile LH release if dosed appropriately (every 90–120 minutes via pump or frequent injections), but most off-label PCT use of Gonadorelin does not approximate physiological pulsatility and the effect on testicular function recovery is therefore questionable.

Kisspeptin-10 acts upstream of GnRH and is the most potent endogenous trigger of GnRH release. Research-grade Kisspeptin-10 has been used in clinical studies of hypogonadotropic hypogonadism with measurable LH/FSH responses. In PCT context, the same concerns about pulsatility apply — single daily injections do not replicate the hypothalamic firing pattern.

hCG is technically a glycoprotein hormone, not strictly a peptide, but it is the most-used 'peptide' in PCT because it directly stimulates Leydig cells to restore intratesticular testosterone and testicular volume. There's no peptide in this guide's catalog that replaces hCG's role.

GHRH analogs and GHRPs (Sermorelin, CJC-1295/Ipamorelin) are sometimes added during PCT for general recovery — sleep, body composition support during the transient hypogonadal window — but they don't directly accelerate HPG axis recovery. Their utility is symptomatic, not mechanistic for testicular function.

What to be skeptical about: claims that BPC-157, TB-500, or similar healing peptides 'support PCT recovery'. These don't act on the HPG axis. Their inclusion in PCT stacks is often pure marketing layered on actual SERM/hCG/AI protocols.

The honest framing: PCT pharmacology that has actual evidence (SERMs, hCG, AIs) is well-developed. Peptides occupy a niche role at best, and most peptide-PCT protocols are layering optional adjuncts on the actual recovery agents.